Abstract: The invention relates to new compounds, 3-phenylpropionic acid derivatives of formula (I) wherein W represents COOH group or its bioisosters, or —COO—C1–C4-alkyl group; Y represents NH, N—C1–C10-alkyl, O, or S; X represents O, S, NH, N—C1–C10-alkyl, N-aryl, NSO2—C1–C10-alkyl, N—SO2-aryl, or N—SO2-heteroaryl; R1 to R8 each independently represents hydrogen atom or a substituent defined in the description; A is as defined in the description; n represents an integer from 0 to 4, inclusive; and pharmaceutically acceptable salts thereof.

Abstract: The invention relates to new compounds, being 3-phenylpropionic acid derivatives of formula I wherein W represents COOH group or its bioisosters, or —COO—C1-C4-alkyl group; Y represents NH, N—C1-C10-alkyl, O, or S; Z represents NH, N—C1-C10-alkyl, N-aryl, N-heteroaryl, S, or O; X represents O, S, NH, N—C1-C10-alkyl, N-aryl, NSO2—C1-C10-alkyl, N—SO2-aryl, or N—SO2-heteroaryl; R1 to R8 each independently represent hydrogen atom or a substituent defined in the description; A is as defined in the description; n represents an integer from 0 to 4, inclusive; and pharmaceutically acceptable salts thereof. The compounds are the ligands of PPAR-gamma receptor and are useful as medicaments.

Abstract: The invention relates to new compounds, being 3-phenylpropionic acid derivatives of formula I wherein W represents COOH group or its bioisosters, or —COO—C1-C4-alkyl group; Y represents NH, N—C1-C10-alkyl, O, or S; Z represents NH, N—C1-C10-alkyl, N-aryl, N-heteroaryl, S, or O; X represents O, S, NH, N—C1-C10-alkyl, N-aryl, NSO2—C1-C10-alkyl, N—SO2-aryl, or N—SO2-heteroaryl; R1, to R6 each independently represent hydrogen atom or a substituent defined in the description; A is as defined in the description; n represents an integer from 0 to 4, inclusive; and pharmaceutically acceptable salts thereof. The compounds are the ligands of PPAR-gamma receptor and are useful as medicaments.

Abstract: The invention relates to new compounds, 3-phenylpropionic acid derivatives of formula (I) wherein W represents COOH group or its bioisosters, or —COO—C1-C4-alkyl group; Y represents NH, N—C1-C10-alkyl, O, or S; X represents O, S, NH, N—C1-C10-alkyl, N-aryl, NSO2—C1-C10-alkyl, N—SO2-aryl, or N—SO2-heteroaryl; R1 to R8 each independently represent hydrogen atom or a substituent defined in the description; A is as defined in the description; n represents an integer from 0 to 4, inclusive; and pharmaceutically acceptable salts thereof. The compounds are the ligands of PPAR-gamma receptor and are useful as medicaments.

Abstract: A method of treating overactive bladder in women involves inserting an intravaginal device of substantially spherical shape and a diameter that fits the width of the vagina into the vagina above the levator ani muscle, and maintaining said device in the appropriate location inside the vagina for an extended period of time to exert its therapeutic effect. The method may further comprise performing pelvic floor exercises, preferably exercises consisting of contracting the levator ani muscle and squeezing soft objects between the knees while in a prone position, preferably twice a day, with said device left inside the vagina.

Abstract: The invention provides a novel association of polyvinylpyrrolidone with chlorin p6 and/or its salt with a pharmaceutically acceptable counter-ion and a method of preparation thereof. Preferably, the weight ratio of chlorin p6 and/or its salt with a pharmaceutically acceptable counter-ion to polyvinylpyrrolidone is contained within the range from about 1:1 to about 1:200. The association can be used as a photosensitizer in photodynamic therapy and/or diagnostics or for photochemical internalization of molecules as well as a photosensitizer in cosmetology. The invention provides also a pharmaceutical composition containing the novel association, a method of treating and diagnosing diseases by a dynamic phototherapy and a method of performing cosmetic procedures with the use of the novel association as a photosensitizer.

Abstract: An intravaginal set and a method of treatment of prolaps of urogenital organs and urinary stress incontinence or in the period of intervals in women when the intravaginal therapeutic insert for treatment of static disorders of the urogenital organs and urinary stress incontinence is not currently inserted, said method being realised by means of an intravaginal set of inserts, characterized by selecting the appropriate size of corrective insert from a subset of intravaginal corrective inserts, consisting of at least two balls with step increase in diameter, ranging between the minimal and maximal woman vaginal diameter, each ball being preferably hollow, each ball has the loosely hanging string and each ball is made preferably of medical material, such as polycarbonate or methyl methacrylate, said selecting being realised by means of an intravaginal measuring subset comprising at least two metal or plastic balls having graduated diameters corresponding to graduated diameters of the balls from the subset of the

Abstract: A method of treating overactive bladder in women involves inserting an intravaginal device of substantially spherical shape and a diameter that fits the width of the vagina into the vagina above the levator ani muscle, and maintaining said device in the appropriate location inside the vagina for an extended period of time to exert its therapeutic effect. The method may further comprise performing pelvic floor exercises, preferably exercises consisting of contracting the levator ani muscle and squeezing soft objects between the knees while in a prone position, preferably twice a day, with said device left inside the vagina.